Fulcrum Historical Financial Ratios

FULC Stock  USD 3.85  0.10  2.53%   
Fulcrum Therapeutics is recently reporting on over 121 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 1.67 or Days Sales Outstanding of 307 will help investors to properly organize and evaluate Fulcrum Therapeutics financial condition quickly.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.

About Fulcrum Financial Ratios Analysis

Fulcrum TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Fulcrum Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Fulcrum financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Fulcrum Therapeutics history.

Fulcrum Therapeutics Financial Ratios Chart

At present, Fulcrum Therapeutics' Days Sales Outstanding is projected to increase significantly based on the last few years of reporting. The current year's Stock Based Compensation To Revenue is expected to grow to 5.54, whereas PTB Ratio is forecasted to decline to 1.67.
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On EquityOperating Cycle
Cash Conversion Cycle

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Fulcrum Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Fulcrum Therapeutics sales, a figure that is much harder to manipulate than other Fulcrum Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.
Most ratios from Fulcrum Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Fulcrum Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.At present, Fulcrum Therapeutics' Days Sales Outstanding is projected to increase significantly based on the last few years of reporting. The current year's Stock Based Compensation To Revenue is expected to grow to 5.54, whereas PTB Ratio is forecasted to decline to 1.67.
 2021 2022 2023 2024 (projected)
Days Sales Outstanding78.2862.21292.65307.28
PTB Ratio2.961.651.761.67

Fulcrum Therapeutics fundamentals Correlations

-0.460.950.23-0.520.32-0.47-0.461.00.460.41-0.560.24-0.50.370.110.210.530.350.54-0.21-0.120.460.460.390.46
-0.46-0.31-0.920.590.230.41.0-0.470.18-0.290.630.270.73-0.81-0.19-0.91-0.46-0.13-0.560.870.44-1.0-0.88-0.55-1.0
0.95-0.310.11-0.310.35-0.35-0.310.940.470.28-0.360.22-0.350.32-0.110.10.370.260.38-0.12-0.190.310.310.280.32
0.23-0.920.11-0.49-0.54-0.4-0.920.24-0.510.07-0.52-0.57-0.450.790.081.00.390.150.46-0.88-0.540.920.840.540.91
-0.520.59-0.31-0.490.270.590.59-0.530.140.040.470.250.47-0.43-0.77-0.5-0.91-0.47-0.980.490.3-0.58-0.83-0.88-0.58
0.320.230.35-0.540.270.450.230.320.970.670.050.94-0.22-0.18-0.02-0.59-0.39-0.41-0.310.320.51-0.22-0.47-0.53-0.2
-0.470.4-0.35-0.40.590.450.4-0.480.220.120.730.280.450.04-0.13-0.43-0.84-0.96-0.620.040.05-0.4-0.58-0.6-0.39
-0.461.0-0.31-0.920.590.230.4-0.470.18-0.290.630.270.73-0.81-0.19-0.91-0.46-0.13-0.560.870.44-1.0-0.88-0.55-1.0
1.0-0.470.940.24-0.530.32-0.48-0.470.460.43-0.580.25-0.510.370.110.230.540.360.54-0.22-0.10.470.460.390.48
0.460.180.47-0.510.140.970.220.180.460.7-0.140.96-0.34-0.240.01-0.55-0.2-0.17-0.180.380.56-0.17-0.38-0.43-0.15
0.41-0.290.280.070.040.670.12-0.290.430.7-0.550.73-0.490.11-0.010.01-0.21-0.19-0.18-0.050.490.3-0.1-0.430.32
-0.560.63-0.36-0.520.470.050.730.63-0.58-0.14-0.55-0.140.72-0.13-0.1-0.51-0.53-0.62-0.390.2-0.21-0.64-0.49-0.23-0.64
0.240.270.22-0.570.250.940.280.270.250.960.73-0.14-0.29-0.40.02-0.61-0.32-0.2-0.320.480.71-0.26-0.52-0.58-0.24
-0.50.73-0.35-0.450.47-0.220.450.73-0.51-0.34-0.490.72-0.29-0.3-0.21-0.45-0.43-0.28-0.440.38-0.06-0.74-0.56-0.29-0.74
0.37-0.810.320.79-0.43-0.180.04-0.810.37-0.240.11-0.13-0.4-0.30.140.770.19-0.30.43-0.96-0.70.80.740.490.8
0.11-0.19-0.110.08-0.77-0.02-0.13-0.190.110.01-0.01-0.10.02-0.210.140.070.580.120.72-0.230.070.180.430.570.18
0.21-0.910.11.0-0.5-0.59-0.43-0.910.23-0.550.01-0.51-0.61-0.450.770.070.420.190.48-0.87-0.570.910.860.570.9
0.53-0.460.370.39-0.91-0.39-0.84-0.460.54-0.2-0.21-0.53-0.32-0.430.190.580.420.770.94-0.25-0.230.450.760.890.44
0.35-0.130.260.15-0.47-0.41-0.96-0.130.36-0.17-0.19-0.62-0.2-0.28-0.30.120.190.770.510.230.110.130.350.480.12
0.54-0.560.380.46-0.98-0.31-0.62-0.560.54-0.18-0.18-0.39-0.32-0.440.430.720.480.940.51-0.47-0.370.550.850.950.54
-0.210.87-0.12-0.880.490.320.040.87-0.220.38-0.050.20.480.38-0.96-0.23-0.87-0.250.23-0.470.67-0.87-0.81-0.54-0.86
-0.120.44-0.19-0.540.30.510.050.44-0.10.560.49-0.210.71-0.06-0.70.07-0.57-0.230.11-0.370.67-0.43-0.58-0.57-0.41
0.46-1.00.310.92-0.58-0.22-0.4-1.00.47-0.170.3-0.64-0.26-0.740.80.180.910.450.130.55-0.87-0.430.870.531.0
0.46-0.880.310.84-0.83-0.47-0.58-0.880.46-0.38-0.1-0.49-0.52-0.560.740.430.860.760.350.85-0.81-0.580.870.880.86
0.39-0.550.280.54-0.88-0.53-0.6-0.550.39-0.43-0.43-0.23-0.58-0.290.490.570.570.890.480.95-0.54-0.570.530.880.52
0.46-1.00.320.91-0.58-0.2-0.39-1.00.48-0.150.32-0.64-0.24-0.740.80.180.90.440.120.54-0.86-0.411.00.860.52
Click cells to compare fundamentals

Fulcrum Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Fulcrum Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fulcrum Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fulcrum Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fulcrum Therapeutics Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.29)
Revenue Per Share
1.317
Quarterly Revenue Growth
89.909
Return On Assets
(0.07)
Return On Equity
(0.07)
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.